1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Janssen’s Amivantamab Combo Shows Promise In First-Line NSCLC

Tagrisso Head-To-Head Set To Begin

 
• By Jung Won Shin

Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator. 

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Achieving Superiority Over Tagrisso Could Be Paradigm Changing • Source: Shutterstock

Janssen Pharmaceutical Cos. has unveiled very promising interim results from the CHRYSALIS study evaluating amivantamab, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET) mutations, in combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib, in patients with non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.

The Phase Ib study results from CHRYSALIS, presented in oral form at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, will lead into the Phase III MARIPOSA study, which will assess the amivantamab/lazertinib combo versus osimertinib (

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.